ENTITY

Mirxes (2629 HK)

32
Analysis
Health Care • Singapore
Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company that develops diagnostic solutions for the early detection of diseases, including cancer, cardiovascular, metabolic, and infectious diseases. Its key products include GASTROClear, a blood-based test for gastric cancer screening, and LUNGClear for lung cancer screening, along with Fortitude COVID-19 RT-qPCR test kits. The company was founded in 2014.
more
•18 Jun 2025 08:44

HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September 2025

There could be 55 changes for the HSCI in September. That could result in 46 changes to the Southbound Stock Connect list and also have...

Logo
1.3k Views
Share
•12 Jun 2025 17:34

Quiddity Leaderboard Hang Seng Biotech Sep25: Three Changes Likely + One Intra-Review Change

Index member Yichang HEC Changjiang Pharma (1558 HK) is involved in a takeover situation which is expected to complete in 2Q 2025. This could...

Share
bearish•PegBio
•26 May 2025 20:58

PegBio IPO Trading Update

​PegBio raises $38m in global offering, set to list on HK Stock Exchange with retail investors holding majority of free float shares.

Logo
505 Views
Share
•26 May 2025 08:08

ECM Weekly (26 May 2025) - CATL, Hengrui, Eastroc, Haitian, Schloss, Aegis, Hyundai Marine, Pony

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
596 Views
Share
bearish•Mirxes
•22 May 2025 23:19

Mirxes IPO Trading Update

​Duality Biotherapeutics raises $140m in global offering, set to list on Hong Kong Stock Exchange with highly concentrated free float shares.

Logo
619 Views
Share
x